Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
23/06/26	SEK 0.4815	-3.51%	176,141
22/06/26	SEK 0.4990	+4.07%	1,042,878
18/06/26	SEK 0.4795	-0.10%	235,407
17/06/26	SEK 0.4800	+0.42%	379,554
16/06/26	SEK 0.4780	+0.74%	661,157

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Delayed Nasdaq Stockholm Other stock markets 12:57:38 23/06/2026 BST			5-day change	1st Jan Change
0.4815 ^SEK	-3.51%		+1.99%	-41.19%

06-12	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
06-08	Alzinova raises SEK 15.2 million before issuance costs	FW

Market Cap	77.33M 8.05M 7.03M 6.51M 6.07M 11.4M 761M 11.49M 30.09M 374M 30.23M 29.57M 1.3B	P/E 2026 *	-1.56x	P/E 2027 *	-1.02x
Enterprise Value	74.33M 7.74M 6.76M 6.25M 5.84M 10.96M 731M 11.04M 28.92M 360M 29.05M 28.42M 1.25B	EV / Sales 2026 *	2.37x	EV / Sales 2027 *	-
Free-Float	82.23%	Yield 2026 *	-	Yield 2027 *	-

06-12	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
06-08	Alzinova raises SEK 15.2 million before issuance costs	FW
05-26	Calendar Tuesday May 26	FW
05-25	Calendar Tuesday May 26	FW
05-21	Alzinova secures 80 percent of TO4 warrants	FW
05-20	Alzinova phase 1b results published in scientific journal	FW
05-20	Alzinova AB Publishes Clinical Results with ALZ-101 in Alzheimer?s Research & Therapy	CI
05-13	Alzinova AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Alzinova Q1 loss after financial items SEK 6 mln	RE
05-13	Alzinova reports narrowed operating loss - CEO: we see rapidly growing commercial interest in diagnostics	FW
05-11	Alzinova article on Alzheimer's vaccine published in scientific journal	FW
05-11	Alzinova AB Announces Clinical Results with Alz-101 to Be Published in Scientific Journal	CI
05-05	Eight stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW

04-08	RX Securities sees potential upside for Alzinova from Alzheimer's diagnostic collaboration	FW
03-26	DNB Carnegie sees reduced financing risk for Alzinova, but partnership remains critical	FW
06/10/25	Alzinova gets fast track designation from US FDA	RE
06/10/25	Alzinova's Alzheimer's Disease Vaccine Candidate Gets Fast-track Designation from US FDA	MT
04/10/25	Alzinova AB Receives Fast Track Designation from US FDA for ALZ-101 in Alzheimer's Disease	CI

Alzinova AB Share Price

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news : Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Course Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

06-12	Warrants of series TO4 were exercised to approximately 94.2 percent and the Company will receive approximately 15.3 million	AQ
06-08	Alzinova announces preliminary outcome of the exercise of warrants of series TO4	AQ
06-03	The last day of trading with the warrants of series TO4 in Alzinova is today, June 3, 2026	AQ
05-26	Bulletin from the Annual General Meeting of Alzinova AB (publ)	AQ
05-25	The subscription price for warrants of series TO4 in Alzinova has been determined to SEK 0.32 and the exercise period begins today	AQ

1 day	-2.30%
1 week	+1.99%
Current month	+13.24%
1 month	+1.56%
3 months	-20.08%
6 months	-40.55%
Current year	-41.19%

1 week	0.46	0.52
1 month	0.41	0.58
Current year	0.38	0.97
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	9.18
10 years	0.38	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	30/09/2024
Anders Sandberg COO	Chief Operating Officer	54	16/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	26/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	31/08/2015
Anders Waas BRD	Director/Board Member	69	31/12/2017
Carol Routledge BRD	Director/Board Member	-	31/12/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	-3.51%	+1.99%	-71.32%	-84.27%	8.05M
LONZA GROUP AG	+2.46%	+3.68%	-8.63%	-3.25%	43.24B
REVOLUTION MEDICINES, INC.	+1.73%	+3.59%	+318.08%	+564.04%	35.25B
BEONE MEDICINES AG	+0.61%	+1.34%	+10.00%	+46.20%	30.22B
IQVIA HOLDINGS INC.	+0.02%	-5.93%	+8.45%	-21.44%	28.01B
CELLTRION, INC.	-1.06%	-3.71%	+9.08%	+19.56%	24.08B
ASCENDIS PHARMA A/S	-1.23%	+2.11%	-	-	14.16B
MEDPACE HOLDINGS, INC.	-0.99%	-2.53%	+47.29%	+102.88%	13.01B
EUROFINS SCIENTIFIC SE	+2.05%	+3.32%	+8.87%	+14.53%	12.7B
IONIS PHARMACEUTICALS, INC.	+2.39%	+2.61%	+102.86%	+84.20%	12.54B
Average	+0.15%	+0.28%	+47.19%	+80.27%	21.32B
Weighted average by Cap.	+0.56%	-0.20%	+68.40%	+118.50%

	2026 *	2027 *
Net sales	31.35M 3.26M 2.85M 2.64M 2.46M 4.62M 308M 4.66M 12.2M 152M 12.25M 11.99M 527M	-
Net income	-3.2M -333K -291K -269K -251K -472K -31.48M -475K -1.25M -15.48M -1.25M -1.22M -53.78M	-50.35M -5.24M -4.58M -4.24M -3.95M -7.42M -495M -7.48M -19.59M -244M -19.68M -19.26M -846M
Net Debt	-3M -312K -273K -252K -236K -442K -29.52M -446K -1.17M -14.51M -1.17M -1.15M -50.42M	-7M -729K -637K -589K -550K -1.03M -68.87M -1.04M -2.72M -33.86M -2.74M -2.68M -118M